Discovery and Validation of Protein Abundance Differences between Follicular Thyroid Neoplasms

Department of Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Cancer Research (Impact Factor: 9.33). 04/2008; 68(5):1572-80. DOI: 10.1158/0008-5472.CAN-07-5020
Source: PubMed


Distinguishing between benign follicular thyroid adenoma (FTA) and malignant follicular thyroid carcinoma (FTC) by cytologic features alone is not possible. Molecular markers may aid distinguishing FTA from FTC in patients with indeterminate cytology. The aim of this study is to define protein abundance differences between FTC from FTA through a discovery (proteomics) and validation (immunohistochemistry) approach. Difference gel electrophoresis (DIGE) and peptide mass fingerprinting were performed on protein extracts from five patients with FTC and compared with six patients with FTA. Individual gel comparisons (i.e., each FTC extract versus FTA pool) were also performed for the five FTC patients. Immunohistochemical validation studies were performed on three of the identified proteins. Based on DIGE images, 680 protein spots were matched on individual gels. Of these, 102 spots showed statistically significant differences in abundance between FTC and FTA in the individual gel analyses and were therefore studied further. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to identify 54 of these protein spots. Three candidates involved in protein folding (heat shock protein gp96, protein disulfide isomerase A3, and calreticulin) were studied by immunohistochemistry. Moderate calreticulin immunohistochemical staining was the best single marker with a high negative predictive value (88%); combining all three markers (any marker less than moderate staining) had the best positive predictive value (75%) while still retaining a good negative predictive value (68%). With DIGE, we identified 54 proteins differentially abundant between FTC and FTA. Three of these were validated by immunohistochemistry. These findings provide further insights into the diagnosis, prognosis, and pathophysiology of follicular-derived thyroid neoplasms.

Download full-text


Available from: Brigiet Hoevenaars, Aug 19, 2014
  • Source
    • "A more recent proteomic study 14, which included SELDI-TOF-MS, western blotting analysis, and IHC, similarly revealed a significantly higher expression of S100A6 in PTC in comparison with follicular thyroid carcinoma (FTC) or normal thyroid tissue. Srisomsap et al. 15 focused on the differential protein expression between non-neoplastic and neoplastic thyroid disease, and the most distinctive protein found was cathepsin B. Netea-Maier et al. 16 applied proteomics and IHC tools to identify and confirm potential novel biomarkers that may help distinguish between FTC and follicular thyroid adenoma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The loss of I uptake ability in metastases from differentiated thyroid carcinoma (DTC) is becoming a major obstacle in radioiodine treatment. However, there is no effective way to screen for I uptake ability in metastases. The identification of differentially expressed proteins by serum proteomics may contribute to our understanding of the mechanisms underlying the dedifferentiation of DTC. Serum samples were obtained from papillary thyroid carcinoma patients with non-I-avid lung metastases and I-avid lung metastases. Differential protein analysis was performed using two-dimensional gel electrophoresis. Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting. We found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-I-avid lung metastases. Afamin may be a potential serum biomarker for early screening of I uptake ability in DTC metastases and could therefore be of value in guiding radioiodine treatment decisions.
    Nuclear Medicine Communications 10/2013; 34(12). DOI:10.1097/MNM.0000000000000001 · 1.67 Impact Factor
  • Source
    • "Developments in genomics and molecular biology have shed light on pathogenic mechanisms related to thyroid cancer [2]. Great efforts have been made to identify genes and biomolecules that are differentially expressed in cancerous tissues, which can be utilized as biomarkers to elucidate thyroid cancer pathogenesis and guide appropriate and targeted molecular therapies [3], [4], [5]. Several candidate genes (for TSH receptors, RET/PTC, Ras, BRAF, p53) in the development of different types of thyroid cancer [2] have been identified thus far. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A good prognosis can be expected for most, but not all, cases of thyroid papillary cancer. Numerous molecular studies have demonstrated beneficial treatment and prognostic factors in various molecular markers. Whereas most previous reports have focused on genomics and proteomics, few have focused on lipidomics. With the advent of mass spectrometry (MS), it has become possible to identify many types of molecules, and this analytical tool has become critical in the field of omics. Recently, imaging mass spectrometry (IMS) was developed. After a simple pretreatment process, IMS can be used to examine tissue sections on glass slides with location information. Here, we conducted an IMS analysis of seven cases of thyroid papillary cancer by comparison of cancerous with normal tissues, focusing on the distribution of phospholipids. We identified that phosphatidylcholine (16:0/18:1) and (16:0/18:2) and sphingomyelin (d18:0/16:1) are significantly higher in thyroid papillary cancer than in normal thyroid tissue as determined by tandem mass (MS/MS) analysis. These distributional differences may be associated with the biological behavior of thyroid papillary cancer.
    PLoS ONE 11/2012; 7(11):e48873. DOI:10.1371/journal.pone.0048873 · 3.23 Impact Factor
  • Source
    • "Cancer PDI P Endometrial cancer (with NS-398 treatment) [243] ERp57 P Prostate cancer (metastatic cell lines) [244] PDI, ERp57 P Leukemia (with ascorbate or photodynamic therapy) [245] [246] ERp57 P Esophageal cancer (cell lines) [247] ERp57, PDI P, I, G Gastric cancer (cancer/metastases vs control tissues; in serum, after vs before operation; in chemotherapy-resistant vs nonresistant cells) [248] [249] [250] PDI P, G Human bladder transitional carcinoma (cells) [251] PDIp I Pancreatic cancer (cell lines) [252] ERp57 P, I Glioblastoma multiforme (in astrocytomas) [253] ERp57 P, I Malignant follicular thyroid carcinoma [254] ERp57 P Lung metastatic cancer (cell lines) [255] Neurologic PDI, ERp44 I Neurodegenerative diseases (in ts1-infected astrocytes) [256] PDI P, I Neurologic dysfunction (in immunodeficiency mouse model) [257] PDI G Traumatic brain injury (in rat model) [258] Inflammation PDI P, I Edematous pancreatitis (in acinar cells) [259] ERp57 P Acute colitis (in colonic mucosa) [260] Others PDI P, I Osteoporosis (in osteoblasts or in circulating monocytes) [261] [262] ERp57 G Toxin exposure (diethylhexyl phthalate, in liver) [263] PDI P Exposure to arsenic and ionizing radiation (in keratinocytes) [264] ERp57 P Chronic vestibular compensation (after unilateral labyrinthectomy) [265] PDI P, I, G Antiphospholipid syndrome (in monocytes) [266] ERp57, ERp46, ERp29 P, I Insulin resistance and dyslipidemia (in hepatocytes) [229] ERp72, ERp57 P Caloric restriction (in liver) [201] ERp57 P Idiopathic pulmonary fibrosis (in bronchoalveolar fluid) [267] PDI P Obstructive sleep apnea syndrome (in kidney) [242] ERp57 P Preeclamptic trophoblasts [217] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thiol proteins may potentially act as redox signaling adaptor proteins, adjusting reactive oxygen species intermediates to specific signals and redox signals to cell homeostasis. In this review, we discuss redox effects of protein disulfide isomerase (PDI), a thioredoxin superfamily oxidoreductase from the endoplasmic reticulum (ER). Abundantly expressed PDI displays ubiquity, interactions with redox and nonredox proteins, versatile effects, and several posttranslational modifications. The PDI family contains >20 members with at least some apparent complementary actions. PDI has oxidoreductase, isomerase, and chaperone effects, the last not directly dependent on its thiols. PDI is a converging hub for pathways of disulfide bond introduction into ER-processed proteins, via hydrogen peroxide-generating mechanisms involving the oxidase Ero1α, as well as hydrogen peroxide-consuming reactions involving peroxiredoxin IV and the novel peroxidases Gpx7/8. PDI is a candidate pathway for coupling ER stress to oxidant generation. Emerging information suggests a convergence between PDI and Nox family NADPH oxidases. PDI silencing prevents Nox responses to angiotensin II and inhibits Akt phosphorylation in vascular cells and parasite phagocytosis in macrophages. PDI overexpression spontaneously enhances Nox activation and expression. In neutrophils, PDI redox-dependently associates with p47phox and supports the respiratory burst. At the cell surface, PDI exerts transnitrosation, thiol reductase, and apparent isomerase activities toward targets including adhesion and matrix proteins and proteases. Such effects mediate redox-dependent adhesion, coagulation/thrombosis, immune functions, and virus internalization. The route of PDI externalization remains elusive. Such multiple redox effects of PDI may contribute to its conspicuous expression and functional role in disease, rendering PDI family members putative redox cell signaling adaptors.
    Free Radical Biology and Medicine 03/2012; 52(9):1954-69. DOI:10.1016/j.freeradbiomed.2012.02.037 · 5.74 Impact Factor
Show more